Your browser doesn't support javascript.
loading
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy.
Pelly, Victoria S; Moeini, Agrin; Roelofsen, Lisanne M; Bonavita, Eduardo; Bell, Charlotte R; Hutton, Colin; Blanco-Gomez, Adrian; Banyard, Antonia; Bromley, Christian P; Flanagan, Eimear; Chiang, Shih-Chieh; Jørgensen, Claus; Schumacher, Ton N; Thommen, Daniela S; Zelenay, Santiago.
Afiliação
  • Pelly VS; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Moeini A; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Roelofsen LM; Divison of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Bonavita E; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Bell CR; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Hutton C; Systems Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Blanco-Gomez A; Systems Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Banyard A; Flow Cytometry, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Bromley CP; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Flanagan E; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Chiang SC; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Jørgensen C; Systems Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom.
  • Schumacher TN; Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Thommen DS; Divison of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Zelenay S; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, United Kingdom. Santiago.Zelenay@cruk.manchester.ac.uk.
Cancer Discov ; 11(10): 2602-2619, 2021 10.
Article em En | MEDLINE | ID: mdl-34031121
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Anti-Inflamatórios / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Anti-Inflamatórios / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido